Recordati Industria Chimica E Farmaceutica (RCDTF) Projected to Post Quarterly Earnings on Thursday

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) is anticipated to announce its resultson Thursday, March 19th. Analysts expect the company to announce earnings of $0.8570 per share and revenue of $769.7510 million for the quarter.

Recordati Industria Chimica E Farmaceutica Price Performance

Shares of RCDTF opened at $56.95 on Wednesday. The company’s fifty day moving average price is $62.89 and its 200-day moving average price is $64.54. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.64 and a quick ratio of 1.16. The firm has a market capitalization of $11.75 billion, a PE ratio of 16.90 and a beta of 0.28. Recordati Industria Chimica E Farmaceutica has a 1-year low of $49.00 and a 1-year high of $65.44.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Barclays upgraded Recordati Industria Chimica E Farmaceutica from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 12th. Kepler Capital Markets upgraded shares of Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 3rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Recordati Industria Chimica E Farmaceutica currently has an average rating of “Buy”.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.